Company intelligence / Profile preview

Thioredoxin Systems AB

Ownership: Private
Development stage: Preclinical

Overview

Thioredoxin Systems AB is developing EbsArgent™, an innovative antibacterial treatment targeting the bacterial antioxidant redox system. The regimen combines ebselen, which disables the essential thioredoxin enzyme system in bacteria, with silver ions to enhance uptake. This approach has demonstrated high bactericidal activity against multidrug-resistant bacteria, including those classified as critical or urgent threats by WHO and CDC. The technology shows promise for efficacy and safety with low mammalian toxicity[1][2].

Therapeutic areas: Infectious Diseases
Modalities: Small molecules (ebselen)Metal ions (silver ions)
Industry: Biotech

Drug pipeline

2 assets

Thioredoxin

Unknown

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Thioredoxin Systems AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Thioredoxin Systems AB.

Explore the full profile